183 related articles for article (PubMed ID: 20506157)
41. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
42. IL-1 plays an important role in the bone metabolism under physiological conditions.
Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
[TBL] [Abstract][Full Text] [Related]
43. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats.
Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD
Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990
[TBL] [Abstract][Full Text] [Related]
44. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
45. Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells.
Liu J; Yang H; Liu W; Cao X; Feng X
J Cell Biochem; 2005 Nov; 96(4):716-27. PubMed ID: 16052479
[TBL] [Abstract][Full Text] [Related]
46. Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells.
Nukaga J; Kobayashi M; Shinki T; Song H; Takada T; Takiguchi T; Kamijo R; Hasegawa K
J Periodontol; 2004 Feb; 75(2):249-59. PubMed ID: 15068113
[TBL] [Abstract][Full Text] [Related]
47. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.
Heider U; Zavrski I; Jakob C; Bängeroth K; Fleissner C; Langelotz C; Possinger K; Hofbauer LC; Viereck V; Sezer O
J Cancer Res Clin Oncol; 2004 Aug; 130(8):469-74. PubMed ID: 15205949
[TBL] [Abstract][Full Text] [Related]
48. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.
Corso A; Ferretti E; Lunghi M; Zappasodi P; Mangiacavalli S; De Amici M; Rusconi C; Varettoni M; Lazzarino M
Cancer; 2005 Jul; 104(1):118-25. PubMed ID: 15895374
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1alpha,25(OH)D.
Sipos W; Duvigneau JC; Schmoll F; Exel B; Hofbauer G; Baravalle G; Hartl RT; Dobretsberger M; Pietschmann P
J Vet Med A Physiol Pathol Clin Med; 2005 Oct; 52(8):382-7. PubMed ID: 16176565
[TBL] [Abstract][Full Text] [Related]
50. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
[TBL] [Abstract][Full Text] [Related]
51. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.
Xu G; Liu K; Anderson J; Patrene K; Lentzsch S; Roodman GD; Ouyang H
Blood; 2012 May; 119(18):4205-14. PubMed ID: 22427205
[TBL] [Abstract][Full Text] [Related]
52. IL-1 mediates TNF-induced osteoclastogenesis.
Wei S; Kitaura H; Zhou P; Ross FP; Teitelbaum SL
J Clin Invest; 2005 Feb; 115(2):282-90. PubMed ID: 15668736
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
Duplomb L; Baud'huin M; Charrier C; Berreur M; Trichet V; Blanchard F; Heymann D
Endocrinology; 2008 Jul; 149(7):3688-97. PubMed ID: 18403479
[TBL] [Abstract][Full Text] [Related]
54. [The role of RANK/RANKL and OPG in multiple myeloma].
Zdzisińska B; Kandefer-Szerszeń M
Postepy Hig Med Dosw (Online); 2006; 60():471-82. PubMed ID: 17013366
[TBL] [Abstract][Full Text] [Related]
55. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
56. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
57. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
58. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
59. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
[TBL] [Abstract][Full Text] [Related]
60. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.
Xiong Y; Donovan KA; Kline MP; Gornet MK; Moon-Tasson LL; Lacy MQ; Dispenzieri A; Gertz MA; Greipp PR; Lust JA
J Interferon Cytokine Res; 2006 Feb; 26(2):83-95. PubMed ID: 16487028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]